Zai Lab (ZLAB) stock moved after recent trading left it around $18, drawing attention to how its current valuation lines up with its multi-therapy biopharmaceutical portfolio and ongoing commercialization efforts.

Over the past year, Zai Lab’s share price return has been mixed, with short term moves around the recent US$18 level contrasting with a 1 year total shareholder return that has fallen 48.53%, while the 5 year total shareholder return is down 89.77%.

If you are comparing Zai Lab with other health focused growth stories, it could be worth scanning for opportunities in 40 healthcare AI stocks

With Zai Lab now trading near US$18 after steep multi year share price declines, the key question is whether the stock sits at a discount to its drug portfolio and growth plans, or if the market already reflects its prospects.

Most Popular Narrative: 46% Undervalued

With Zai Lab stock last closing at $18.00 against a narrative fair value of $33.30, the current gap centers on how quickly its pipeline could translate into larger revenue and a path toward stronger margins.

Multiple high-potential product launches and label expansions over the next 12-18 months (including VYVGART, bemarituzumab, KarXT, TIVDAK, Tumor Treating Fields), combined with a deep pipeline in oncology and immunology, are expected to significantly increase Zai Lab's addressable market and diversify revenue streams, supporting both top-line growth and future earnings.

Want to see what is baked into that $33.30 fair value for Zai Lab? The narrative leans on fast compounding revenue, a sharp profit margin shift and a richer future earnings multiple than the wider biotech sector. Curious how those moving parts fit together.

Result: Fair Value of $33.30 (UNDERVALUED)

However, the bullish Zai Lab narrative still faces pressure from heavy reliance on in licensed assets and intense oncology competition in China, which could squeeze future margins and revenue.

Next Steps

If this Zai Lab narrative seems finely balanced between concern and optimism, consider reviewing the details yourself and weighing both sides using the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Zai Lab?

Do not stop at Zai Lab. Broaden your watchlist with fresh stock ideas surfaced by the Simply Wall Street Screener before the next round of opportunities moves ahead without you.

• Target potential value opportunities by scanning companies that currently screen as 44 high quality undervalued stocks.
• Strengthen your downside protection by focusing on businesses highlighted in the 69 resilient stocks with low risk scores.
• Spot under-the-radar opportunities early by reviewing the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.